Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.